Oxford BioMedica To Provide RPR Gencell With Hypoxia Technology
Rhone-Poulenc Rorer is broadening its relationship with Oxford BioMedica to include a license to the U.K. biotech's hypoxia response element (HRE) gene therapy technology in RPR Gencell's cardiovascular products.
You may also be interested in...
Hoechst Marion Roussel is expanding its development deal with Vertex for the anti-inflammatory agent HMR 3480/VX-740 to include U.S. marketing rights, the firms said Sept. 1.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011